Literature DB >> 25882800

An interlaboratory quality control programme for the measurement of tuberculosis drugs.

Rob E Aarnoutse1, Marieke G G Sturkenboom2, Karen Robijns3, Anneke R Harteveld3, Ben Greijdanus2, Donald R A Uges2, Daniel J Touw4, Jan-Willem Alffenaar2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25882800     DOI: 10.1183/09031936.00177014

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  9 in total

1.  Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry.

Authors:  Jan-Willem C Alffenaar; Mathieu Bolhuis; Kai van Hateren; Marieke Sturkenboom; Onno Akkerman; Wiel de Lange; Ben Greijdanus; Tjip van der Werf; Daan Touw
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

Review 2.  Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.

Authors:  Johanna Kuhlin; Marieke G G Sturkenboom; Samiksha Ghimire; Ioana Margineanu; Simone H J van den Elsen; Noviana Simbar; Onno W Akkerman; Erwin M Jongedijk; Remco A Koster; Judith Bruchfeld; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Clin Mass Spectrom       Date:  2018-10-19

3.  Clinical standards for the dosing and management of TB drugs.

Authors:  J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2022-06-01       Impact factor: 3.427

4.  Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.

Authors:  Marieke G G Sturkenboom; Leonie W Mulder; Arthur de Jager; Richard van Altena; Rob E Aarnoutse; Wiel C M de Lange; Johannes H Proost; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

Review 5.  Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.

Authors:  Ben J Marais; Anna D Heemskerk; Suzaan S Marais; Reinout van Crevel; Ursula Rohlwink; Maxine Caws; Graeme Meintjes; Usha K Misra; Nguyen T H Mai; Rovina Ruslami; James A Seddon; Regan Solomons; Ronald van Toorn; Anthony Figaji; Helen McIlleron; Robert Aarnoutse; Johan F Schoeman; Robert J Wilkinson; Guy E Thwaites
Journal:  Clin Infect Dis       Date:  2017-02-15       Impact factor: 9.079

6.  Standardized approaches for clinical sampling and endpoint ascertainment in tuberculous meningitis studies.

Authors:  Ursula K Rohlwink; Felicia C Chow; Sean Wasserman; Sofiati Dian; Rachel Pj Lai; Lidya Chaidir; Raph L Hamers; Robert J Wilkinson; David R Boulware; Fiona V Cresswell; Arjan van Laarhoven
Journal:  Wellcome Open Res       Date:  2020-06-03

7.  Practices of therapeutic drug monitoring in tuberculosis: an international survey.

Authors:  Ioana Margineanu; Onno Akkerman; Dario Cattaneo; Delia Goletti; Deborah J E Marriott; Giovanni Battista Migliori; Fuad Mirzayev; Charles A Peloquin; Ymkje Stienstra; Jan-Willem Alffenaar
Journal:  Eur Respir J       Date:  2022-04-14       Impact factor: 33.795

8.  A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis.

Authors:  Stijn W van Beek; Rob Ter Heine; Jan-Willem C Alffenaar; Cecile Magis-Escurra; Rob E Aarnoutse; Elin M Svensson
Journal:  Clin Pharmacokinet       Date:  2021-02-22       Impact factor: 6.447

9.  First international quality control programme for laboratories measuring antimicrobial drugs to support dose individualization in critically ill patients.

Authors:  E Wallenburg; R J Brüggemann; K Asouit; M Teulen; A F J de Haan; E J F Franssen; R E Aarnoutse
Journal:  J Antimicrob Chemother       Date:  2021-01-19       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.